Results 11 to 20 of about 59,797 (283)

Dopamine agonists for restless legs syndrome 

open access: yesAdvances in Clinical Neuroscience & Rehabilitation
Restless Legs Syndrome (RLS) is a common neurological disorder characterised by an uncontrollable urge to move the legs. Dopamine agonists are widely used as first or second-line treatments for RLS due to their efficiency in alleviating the symptoms of ...
Pran Phakdeekitcharoen, Michael J Keogh
doaj   +2 more sources

Dopamine Partial Agonists in Pregnancy and Lactation: A Systematic Review

open access: yesPharmaceuticals
Background/Objectives: Dopamine partial agonists are drugs initially developed to treat schizophrenia, seeking a double effect of increased dopaminergic transmission in the prefrontal cortex and decrease in the accumbens/striatum.
Alexia Koukopoulos   +13 more
doaj   +3 more sources

From Selye’s and Szabo’s Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities

open access: yesPharmaceuticals, 2023
We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric   +24 more
doaj   +1 more source

Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease

open access: yesClinical Parkinsonism & Related Disorders, 2021
Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall   +5 more
doaj   +1 more source

Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]

open access: yesPLoS ONE, 2014
BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko   +4 more
doaj   +1 more source

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it

open access: yesAlʹmanah Kliničeskoj Mediciny, 2023
The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj   +1 more source

Dopamine agonists and antipsychotics [PDF]

open access: yesEuropean Journal of Endocrinology, 2020
There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire   +2 more sources

Impulsivity in Patients with Parkinson’s Disease [PDF]

open access: yesJournal of Biomedical & Clinical Research, 2017
In recent years focus has been increasingly placed on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD). ICDs include pathological attraction to gambling, compulsive shopping, compulsive eating and compulsive sexual behaviour and
Rumyana Kuzmanova   +2 more
doaj   +3 more sources

Predictors of dopamine agonist resistance in prolactinoma patients

open access: yesBMC Endocrine Disorders, 2020
Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy